Clinical effects of sex steroids on the brain

Menopause

Volumn , Issue , 2007, Pages 199-215

  Da Sllva, Ivaldo ^a   Naftolin, Frederick ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882896899     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369443-0/50019-3     Document Type: Chapter

References (146)

1. Burger HG Physiological principles of endocrine replacement: estro-gen. Harm Res 2001, 56(suppl l):82-85.
2. Ratka A, Miller V, Brown K, et al. Menopausal Vasomotor Symptoms (MVS) survey for assessment of hot flashes. J Womens Health (Larchmt) 2006, 15. Jan-Feb.
3. Maclennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 2006, 13:28-36.
4. Bachmann GA Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 2005, 50:155-165.
5. McCullough LD, Hum PD Estrogen and ischemic neuroprotection: an integrated view. Trends Endocrinol Metab 2003, 14:228-235.
6. Barsom SH, Mansfield PK, Koch PB, Gierach G, West SG Associa-tion between psychological stress and menstrual cycle characteristics in perimenopausal women. Womens Health Issues 2004, 14:235-241.
7. Morris JC, Price Al Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001, 17:101-118.
8. Gibson CL, Gray LJ, Murphy SP, Bath PM Estrogens and experi-mental ischemic stroke: a systematic review. J Cereb Blood Flow Metab 2006, 25. Jan.
9. Naftolin F Brain aromatization of androgen. J Reprod Med 1994, 39:257-261.
10. Silva I, Mor G, Naftolin F Estrogen and the aging brain. Maturitas 2001, 38:95-100.
11. Azcoitia I, Sierra A, Veiga S, Garcia-Segura LM Aromatase expres-sion by reactive astroglia is neuroprotectiveAnn. N Y Acad Sci 2003, 1007:298-305.
12. Hung AJ, Stanbury MG, Shanabrough M, et al. Estrogen, synaptic plasticity and hypothalamic reproductive aging. Exp Gerontol 2003, 38:53-59.
13. Reichlin S Neuroendocrinology. Williams textbook of endocrinology 1995, 13-19. WB Saunders, Philadelphia. 8 ed. J. Wilson, D. Foster (Eds.).
14. Naftolin F, Leranth C, Horvath T, Garcia-Segura L Potential neuro-nal mechanisms of estrogen actions in synaptogenesis and synaptic plasticity. Cell Mol Neurobiol 1996, 16:213-223.
15. Woolley CS, Weiland NG, McEwen BS, Schwartzkroin PA Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 1997, 17:1848-1859.
16. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estro-gens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 23:2959-2968.
17. Maki PM Estrogen effects on the hippocampus and frontal lobes. Int J Fertil Womens Med 2005, 50:67-71.
18. Craig MC, Maki PM, Murphy DG The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 2005, 4:190-194.
19. Maki PM Potential importance of early initiation of hormone therapy for cognitive benefit. Menopause 2006, 13:6-7.
20. Olmos G, Naftolin F, Perez J, Tranque P, Garcia-Segura LM Synaptic remodeling in the rat arcuate nucleus during estrus cycle. Neuroscience 1989, 32:663-667.
21. Negri-Cesi P, Poletti A, Celotti F Metabolism of steroids in the gain: a new insight into the role of the 5-alpha-reductase and aromatase in the brain differentiation and functions. J. Steroid Biochem Mol Bill 1996, 58:455-466.
22. Paul SM, Purdy RH Neuroactive steroids. FASEB J 1992, 6:2311-2322.
23. Pluchino N, Genazzani AD, Bernardi F, et al. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating al-lopregnanolone, cortisol and dehydroepiandrosterone levels. Gynecol Endocrinol 2005, 20:144-149.
24. Mor G, Nilsen J, Horvath T, et al. Estrogen and microglia: a regulatory system that affects the brain. J Neurobiol 1999, 40:484-496.
25. Bechmann I, Mor G, Nilsen, et al. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain-evidence for the existence of an immunological brain barrier. Glia 1999, 27:62-74.
26. Bechmann I, Goldmann J, Kovac AD, et al. Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia. FASEB J 2005, 19:647-649.
27. Mor G, Sapi E, Abrahams VM, et al. Interaction of the estrogen recep-tors with the Fas ligand promoter in human monocytes. J Immunol 2003, 170:114-122.
28. Nilsen J, Mor G, Naftolin F Estrogen-regulated developmental neuro-nal apoptosis is determined by estrogen receptor subtype and the Fas/ Fas ligand system. J Neurobiol 2000, 43:64-78.
29. Honjo H, Iwasa K, Kawata M, et al. Progestins and estrogens and Alzheimer's disease JSteroid. Biochem 2005, 93 Mol Biol:305-308.
30. Alvarez De La Rosa M, Silva I, Nilsen J, et al. Estradiol prevents neu-ral tau hyperphosphorylation characteristic of Alzheimer's disease. Ann N Y Acad Sci 2005, 1052:210-224.
31. Korak KS, Migliaccio S, Basis VL Estrogens. Principles of pharmacology: basic concepts and clinical implications 1994, 809-826. Chapman & Hall, New York. P. Munson, R. Mueller, G. Breese (Eds.).
32. MacGregor J, Tonetti D, Craig Jordan V The complexity of selective estrogen receptor modulation: the design of a postmenopausal prevention maintenance therapy. Estrogens and antiestrogens 1997, Lippincott-Raven Publishers, Philadelphia. R. Linsday, D. Dempster, J.V. Craig (Eds.).
33. Mosselman S, Polman J, Dijkema R ER beta: identification and char-acterization of a novel human estrogen receptor. FEBS Lett 1996, 392:49-53.
34. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996, 93:5925-5930.
35. Giguere V, Tremblay A, Tremblay GB Estrogen receptor beta: re-evaluation of estrogen and antiestrogen signaling. Steroids 1995, 63:335-339.
36. Kuiper G, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA Comparison of the ligand binding specificity and tran-script tissue distribution of estrogen receptors alpha and beta. Endocri-nology 1997, 3:863-870.
37. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at API sites. Science 1997, 277:1508-1510.
38. Landers J, Spelsberg T New concepts in steroid hormone action: transcription factors, proto-oncoeenes and the cascade model for steroid regulation of gene expression. Critical review of eukaryotic gene expression 1992, CRC Press, Boca Raton. FL. G. Stein, J. Stein, L. Lian (Eds.).
39. MacLusky NJ, McEwen BS Progestin receptors in the developing rat brain and pituitary. Brain Res 1980, 189:262-268.
40. McEwen B, Davis P, Gerlach J, et al. Progestin receptors in the brain and pituitary gland. Progesterone and progestin 1953, Raven Press, New York. C. Bardin, E. Milgrom, I. Mauvais-Jarvis (Eds.).
41. Shughrue PL, Lane MV, Merchenthaler I Comparative distribution of estrogen receptor-alpha and-beta mRNA in the rat central nervous system. J Comp Neurol 1997, 388:507-515.
42. Laflamme N, Nappi RE, Drolet G, Labrie C, Rivest S Expression and neuropeptidergic characterization of estrogen receptor (ER alpha and beta) thought the rat brain: anatomical evidence of district role of each. J Neurobiol 1998, 36:357-378.
43. Honjo H, Tamura T, Matsumoto Y, et al. Estrogen as a growth factor to central nervous cells. J Steroid Biochem Mol Biol 1992, 41:633-635.
44. MacLusky NJ, Naftolin F Sexual differentiation of central nervous system. Science 1981, 211:1294-1302.
45. Rocca WA, Amaducci LA, Schoenberg BS Epidemiology of clinically diagnosed Alzheimer's disease. Ann Neurol 1986, 19:415-424.
46. Jorm AF, Korten AE, Henderson AS The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatry Scand 1987, 76:465-479.
47. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1930-1990 findings Eurodem Preva-lence Research Group. Int J Epidemiol 1991, 20:736-748.
48. Naftolin F, Leranth C, Perez J, Garcia-Segura LM Estrogen induced synaptic plasticity in adult primate neurons. Neuroendocrinology 1993, 57:935-939.
49. Jakab RL, Horvath TL, Leranth C, Harada N, Naftolin F Aromatase immunoreactivity in the rat brain: gonadectomy sensitive hypothalamic neurons and an oil responsive "limbic ring" of the lateral septum-bed nucl. J Steroid Biochem Mol Biol 1993, 44:481-498.
50. Rybo G, Westemberg H Symptoms in the postmenopause-a popula-tion study: a preliminary report. Acta Obstet Gynecol Scand 1971, 9:25.
51. Thompson B, Hart S, Durno D Menopausal age and symptomatology in general practice. J Biases Sci 1973, 5:71-82.
52. Erlik Y, Tataryn LV, Meldrum DR, et al. Association of waking epi-sodes with menopausal hot flash. JAMA 1981, 245:1741-1744.
53. Phillips SM, Sherwin BB Effects of estrogen in memory function in surgically menopausal women. Psychoneuroendocrinology 1992, 17:485-495.
54. Rosenberg J, Larsen SH Hypothesis: pathogenesis of postmenopausal hot flush. Med Hypotheses 1991, 35:349-350.
55. Meldrum DR, Tataryn LV, Frumar AM, et al. Gonadotropins, estrogens, and adrenal steroids during the menopausal hot flash. J Clin Endocrinol Metab 1950, 50:685-689.
56. Greene R, Kletzky O, Cabus E, Naftolin F Similarities between peripheral perfusion augmentation changes induced by postpartum lactation and postmenopausal hot flushes. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation 1994.
57. Smith J Management of hot flushes due to endocrine therapy for prostate carcinoma. Oncology 1996, 10:1319-1322.
58. Hardt W, Schmidt-Gollwitzer M Sustained gonadal suppression in fertile women with the LHRH agonist buserelin. Clin Endocrinol 1983, 19:613-617.
59. Tham DM, Gardner C, Haskell W Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998, 83:2223-2235.
60. Kupfer D The sleep LEG in diagnosis and treatment of depression. Depression, basic mechanisms diagnosis and treatment 1986, Guilford, New York. A. Rush, K. Altshuler (Eds.).
61. Keefe DL, Watson R, Naftolin F Hormone replacement therapy alle-viated sleep apnea in menopausal women: a pilot study. Menopause 1999, 6:196-200.
62. Shaver J, Giblin E, Lents M, Lee K Sleep patterns and stability in perimenopausal women. Sleep 1988, 11:556-561.
63. Avid NE, Crawford SL, McKinlay SM Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 1997, 3:103-120.
64. Thomson J Double blind study on the effect of estrogen on sleep, anxiety and depression in perimenopausal women: preliminary results. Proc R Soc Med 1976, 69:829-830.
65. Scharf MB, McDannold MD, Stover R, Zaretsky N, Berkowitz DV Effects of estrogen replacement therapy on rated of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study. Clin Ther 1997, 19:304-311.
66. Schiff I, Regestein Q, Tulehinisky D, et al. Effects of estrogens on sleep and psychological slate of hypogonadal women. JAMA 1979, 212:2405.
67. Weissman M, Bland R, Canino G Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996, 276:293-299.
68. Parry B Reproduce factors affecting the course of affective illness in women. Psychiatr Clin North Am 1989, 12:207-220.
69. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB Sex depression in the National Comorbidity Survey I: Lifetime preva-lence, chronicity and recurrence. J Affect Discord 1993, 9:85-96.
70. Saks BR, Frank JB, Lowe TL, et al. Depressed mood during pregnancy and the puerperium: Clinical recognition and implications for clinical practice. Am J Psychiatry 1985, 142:728-731.
71. Zweifel JE, O'Brien WH A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997, 22:189-212.
72. Sherwin BB, Gelfand MM Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause. Am J Obstet Gynecol 1984, 148:552-557.
73. Sherwin BB, Gelfand MM Differential symptoms response to paren-teral estrogen and/or androgen administration in surgical menopause. Am J Obstet Gynecol 1985, 151:153-160.
74. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estro-gen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006, 91:1802-1810.
75. Schmidt P, Roca C, Ribinow D Perimenopausal depression. Perimenopause 1997, 246-254. Springer, New York. R. Lobo (Ed.).
76. Keefe D, Naftolin F Brain neurochemistry and mood. Modern management of premenstrual syndrome 1992, 55-70. WW Norton, New York. S. Smith, I. Schiff (Eds.).
77. Slopien R, Meczekalski B, Warenik-Szymankiewics A Relationship between climacteric symptoms and serum serotonin levels in post-menopausal women. Climacteric 2003, 6:53-57.
78. Jacobs PA, Hyland ME An evaluation of the benefits of taking hor-mone replacement therapy with other prescription drugs. Maturitas 2003, 46:273-281.
79. Kirkham C, Hahn PM, Van Vugt DA, Carmichael JA, Reid RL A randomized double blind placebo-controlled cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replace-ment therapy. Obstet Gynecol 1991, 78:93-97.
80. Prior JC, Alojado N, McKay DW, Vigna YM No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double blind placebo controlled crossover trial. Obstet Gynecol 1994, 83:24-28.
81. Myers L, Dixen J, Morissette D, Carmichael M, Davidson JM Effects of estrogen, androgen, and progestin on sexual psychobiology and behavior in postmenopausal semen. J Clin Endocrinol Metab 1990, 70:1124-1131.
82. Sherwin B The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991, 72:336-343.
83. Maki P, Hogervorst E, HRT The menopause HRT and cognitive decline. Best Pract Res Clin Endocrinol Metab 2003, 17:105-122.
84. Schmidt PJ Mood, depression, and reproductive hormones in the meno-pausal transition. Am J Med 2005, 118:54-58.
85. Richards M, Rubinow DR, Daly RC, Schmidt PJ Premenstrual symp-toms and perimenopausal depression. Am J Psychiatry 2006, 163:133-137.
86. Avi NE, Crawford S, Stellato R, Longcope C Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001, 4:243-249.
87. Hunter MS Psychological and somatic experience of the menopause: a prospective study. Psychosom Med 1990, 52:357-367.
88. Hay AG, Bancroft J, Johnstone EC Affective symptoms in women attending a menopause clinic. Br J Psychiatry 1994, 164:513-516.
89. Schmidt P, Roca C, Ribinow D Perimenopausal depression. Perimenopause 1997, 246-254. Springer, New York. R. Lobo (Ed.).
90. Bremner JD, Vythilingam M, Ng CK, et al. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA 2003, 289:3125-3134.
91. Parry B Reproductive related depression in women: phenomena of hormonal kindling?. Postpartum psychiatric illness: a picture puzzle 1992, University of Pennsylvania Press, Philadelphia. J. Hamilton, P. Harberger (Eds.).
92. Yorkers K The association between premenstrual dysphoric disorder and other mood disorder. J Clin Psychiatry 1997, 58(suppl):19-25.
93. Klaiber EL, Brovermen DM, Vogel W, Kobayashi Y Estrogen therapy for severe persistent depression in women. Arch Gen Psychiatry 1979, 36:550-554.
94. Henderson AF, Gregoire AJ, Kumar RD, Studd JW Treatment of se-vere postnatal depression with oestradiol skin patches. Lancet 1991, 338:816-817.
95. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS, Estrogen replacement response to fluoxetine in a multicenter geriatric depression trial Fluoxetine collaborative study group Am J Geriatr Psychiatry 1997, 5:97-106.
96. Wickelgren I Estrogen stakes claim to cognition. Science 1997, 276:675-678.
97. Lupien SJ, McEwen BS The acute effects of corticosteroids on cog-nition: integration of animal and human studies. Brain Res Rev 1997, 24:1-27.
98. Davis SR "Add back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyo-mata uteri J Clin. Endocrinol Metab 1997, 82:702-703.
99. Haskell SG, Richardson ED, Horwitz RI The effects of estrogen replacement therapy on cognitive function in women: a critical review of the literature JClin. Epidemiol 1997, 50:1249-1264.
100. Sherwin BB Estrogen and cognitive functioning in women. Proc Soc Exp BiolMed 1998, 217:17-22.
101. Sherwin B Estrogen and/or androgen replacement therapy and cog-nitive functioning in surgically menopausal women. Psychoneuroendo-crinology 1988, 13:345-355.
102. Shaywitz SE, Naftolin F, Zelterman D, et al. Better oral reading and short-term memory in midlife, postmenopausal women taking estro-gen. Menopause 2003, 10:420-426.
103. Bechman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of Alzheimer type in the Framingham study. Neurology 1992, 42:115-119.
104. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conju-gated equine estrogens on breast cancer and mammography screen-ing in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657.
105. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk age at onset of Alzheimer's disease. Lancet 1996, 348:429-432.
106. Schneck MJ, Sarrel PI, Albakri E, et al. Oral progesterone therapy impairs cerebrovascular reactivity. Stroke 1995, 26:724.
107. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buck-walter JG Estrogen replacement therapy in older women. Arch Neurol 1994, 51:896-900.
108. Yamamoto KR Steroid receptor regulated transcription of specific genes and gene networks. Annu Rev Genet 1985, 19:209-252.
109. Paganini-Hill A, Henderson VW Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994, 140:256-261.
110. Mortel KF, Meyers JS Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci 1995, 7:334-337.
111. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonder-man A, Bacal C, Lingle DD, et al. A prospective study of estrogen re-placement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997, 48:1517-1521.
112. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002, 288:2123-2129.
113. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estro-gen replacement therapy and risk of Alzheimer's disease: a population based case-control study. Am J Epidemiol 1994, 140:262-267.
114. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estro-gens and incidence of probable dementia and mild cognitive impair-ment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2947-2958.
115. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989, 34:521-525.
116. Honjo H, Ogino Y, Naftolin F, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia Alzheimer's type: a placebo-controlled double blind study. Inter Menopause Soc 1993, 1:167-171.
117. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a ran-domized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000, 283:1007-1015.
118. JAMA 2000, 284:2597.
119. Langer RD, Pradhan AD, Lewis CE, et al. Baseline associations between postmenopausal hormone therapy inflammatory hae-mostatic and lipid biomarkers of coronary heart disease The Women's Health Initi. Thromb Haemost 2005, 93:1108-1116.
120. Clarke CL, Sutherland RL Progestin regulation of cellular prolifera-tion. EndocrRev 1990, 11:266-301.
121. Graham J, Clarke C Physiological action of progesterone in target tissues. EndocrRev 1997, 18:502-519.
122. Robel P, Baulieu EE Neurosteroids: biosynthesis and function. Crit Rev Neurobiol 1995, 9:383-394.
123. Poletti A, Rabuffetti M, Celotti F The 5a-reductase in the rat brain. The brain source and target of sex steroids hormones 1996, The Parthenon Publishing Group, London. A. Genazzani, P. Petraglia, R. Purdy (Eds.).
124. Bixo M, Andersson A, Winblad B, Purdy RH, Backstrom T Proges-terone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine state. Brain Res 1997, 764:173-178.
125. Freeman EW, Purdy RH, Coutifaris C, Rickets K, Paul SM Anxio-lytic metabolites of progesterone: correlation with mood and perfor-mance measures following oral progesterone administration to healthy female voluntee. Neuroendocrinology 1993, 58:478-484.
126. Yamamoto KR Steroid receptor regulated transcription of specific genes and gene networks. Annu Rev Genet 1985, 19:209-252.
127. Purdy RH, Morrow AL, Moore PH, Paul SM Stress-induced el-evations of aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991, 88:4553-4557.
128. Selye H The anesthetic effect of steroid hormones. Proc Soc Eur Biol 1941, 46:116-121.
129. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM Steroids hormone metabolites are barbiturate-like modulators of GABA receptor. Science 1986, 232:1004-1007.
130. Kane FJ Evaluation of emotional reactions to oral contraceptive uses. Am J Obstret Gynecol 1976, 126:968-972.
131. Wagner KD Major depression and anxiety disorder associated with Norplant. J Clin Psychiatry 1996, 57:152-157.
132. M Jensvold Nonpregnant reproductive-age women. Part II. Exogenous sex steroid hormones and psychopharmacology. Sex, gender and hormones 1996, American Psychiatric Press, Washington, DC. M. Jenseold, L. Halbreich, J. Hamilton (Eds.).
133. Siddle NC, Fraser D, Whitehead MI, et al. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990, 97:1101-1107.
134. Whitehead MI, Hillard TC, Crook D The role and use of progesto-gens. Obstet 1990, 75 Gynecol:S59-S76.
135. Holst J, Backstrom T, Hammarback S, von Schoultz B Progesteron addition during estrogen replacement therapy-effects on vasomotor symptoms and mood. Maturitas 1989, 11:13-20.
136. Naftolin F, Silver D Is progestogen supplementation of ERT really necessary?. Menopause 2002, 9:1-2.
137. Richman S, Edusa V, Fadiel A, Naftolin F Low-dose estrogen ther-apy for prevention of osteoporosis: working our way back to mono-therapy. Menopause 2006, 13:148-155.
138. Stevenson JC A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity. J Br Menopause Soc 2006, 12(suppl 1):8-10.
139. Warnock JK, Swanson SG, Borel RW, et al. Combined esterified es-trogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal w. Menopause 2005, 12:374-384.
140. Somboonporn W, Davis S, Scif MW, Bell R Testosterone for peri-and postmenopausal women. Cochrane Database Syst Rev 2005, 19:CD004509.
141. Liu JH Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 2005, 118(suppl 2):88-92.
142. Ren X, Noda Y, Mamiya T, Nagai T, Nabeshima T A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the development of morphine dependence and tolerance via c-fos expression linked to the extrac. Behav Brain Res 2004, 152:243-250.
143. Majewska MD Neuronal actions of dehydroepiandrosterone Possible role in brain development aging, memory and affect Ann. N Y Acad Sci 1995, 774:111-120.
144. Morales AJ, Nolan JJ, Nelson JC, Yen SS Effect of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1995, 80:2799.
145. Ravaglia G, Forti P, Maioli F, et al. Dehydroepiandrosterone-sulfate serum levels and common age-related diseases: results from a cross-sectional Italian study of a general elderly population. Exp Gerontol 2002, 37:701-712.
146. Dayal M, Sammel MD, Zhao J, et al. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipidsJ Womens. Health (Larchmt) 2005, 14:391-400.